Americans Are Flying; Airline Stocks Are Not
https://www.fool.com/investing/2024/07/15/americans-are-flying-airline-stocks-are-not/?source=iedfolrf0000001
Jul 15, 2024 - How the airline industry's focus on capacity and being able to supply more flights means fares are low, even in the face of record demand.
0
2 Unstoppable Growth Stocks to Buy and Hold for the Next Decade
https://www.fool.com/investing/2024/07/15/2-unstoppable-growth-stocks-to-buy-and-hold/?source=iedfolrf0000001
Jul 15, 2024 - These elite companies can help you build lasting wealth.
0
2 High-Flying Growth Stocks You Can Buy Right Now Before They Surge Even Higher
https://www.fool.com/investing/2024/07/14/2-high-flying-growth-stocks-you-can-buy-right-now/?source=iedfolrf0000001
Jul 14, 2024 - Shares are up for very good reasons.
0
2 Incredibly Cheap Growth Stocks to Buy Now
https://www.fool.com/investing/2024/07/14/2-incredibly-cheap-growth-stocks-to-buy-now/?source=iedfolrf0000001
Jul 14, 2024 - Price is just one factor to consider.
0
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
https://www.zacks.com/stock/news/2300869/pharma-stock-roundup-lly-to-buy-morphic-pfe-advances-obesity-drug-development?cid=CS-ZC-FT-analyst_blog|stock_roundup-2300869
Jul 12, 2024 - Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.
0
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
https://www.zacks.com/stock/news/2300260/here-s-why-you-should-invest-in-beam-therapeutics-beam-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2300260
Jul 11, 2024 - Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.
0
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
https://www.zacks.com/stock/news/2300219/novo-nordisk-nvo-soars-38-ytd-how-should-you-play-the-stock?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2300219
Jul 11, 2024 - Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
0
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
https://www.zacks.com/stock/news/2300248/novo-nvo-gets-crl-from-fda-for-weekly-basal-insulin-icodec?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2300248
Jul 11, 2024 - Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
0
Why Lilly (LLY) is Poised to Beat Earnings Estimates Again
https://www.zacks.com/stock/news/2298695/why-lilly-lly-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2298695
Jul 09, 2024 - Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
https://www.zacks.com/stock/news/2298543/eli-lilly-lly-to-buy-morphic-for-3-2b-boost-ibd-presence?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2298543
Jul 09, 2024 - Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.
0